Survival benefits with vitamin D receptor activation: New insights since 2003

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 9, 2010, Pages 1704-1709

  Kovesdy, Csaba P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARICALCITOL; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTICLE; CLINICAL TRIAL; DIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; RISK BENEFIT ANALYSIS; SURVIVAL;

CALCITRIOL; EPIDEMIOLOGIC RESEARCH DESIGN; EVIDENCE-BASED MEDICINE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITAMINS;

EID: 77957294474     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02590310     Document Type: Article

References (41)

1. Moe SM, Drueke T, Lameire N, Eknoyan G: Chronic kidney disease-mineral-bone disorder: A new paradigm. Adv Chronic Kidney Dis 14: 3-12, 2007 (Pubitemid 46014534)
2. Eknoyan G, Levin A, Levin N: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004 (Pubitemid 39031360)
4. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of timevarying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006 (Pubitemid 44215354)
5. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793, 2005 (Pubitemid 41716485)
6. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
7. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study. Hemodial Int 11: 340-348, 2007 (Pubitemid 46958589)
8. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT: The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis 46: 925-932, 2005 (Pubitemid 41505468)
9. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187, 2005 (Pubitemid 41623345)
10. Kovesdy CP, Kalantar-Zadeh K: Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 40: 427-440, 2008
11. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005 (Pubitemid 41725150)
12. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW: High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients. Nephrol Dial Transplant 22: 2909-2916, 2007 (Pubitemid 350093423)
13. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73: 1296-1302, 2008 (Pubitemid 351693159)
14. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K: Battleground: Chronic kidney disorders mineral and bone disease- calcium obsession, vitamin d, and binder confusion. Clin J Am Soc Nephrol 3: 168-173, 2008
15. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003 (Pubitemid 36910023)
16. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
17. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK: The survival advantage for haemodialysis patients taking vitamin D is questioned: Findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24: 963-972, 2009
18. Kovesdy CP, Kalantar-Zadeh K: Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73: 1355-1363, 2008 (Pubitemid 351770491)
19. Andress DL: Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 69: 33-43, 2006
20. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005 (Pubitemid 41710323)
21. Hernan MA, Hernandez-Diaz S, Robins JM: A structural approach to selection bias. Epidemiology 15: 615-625, 2004
22. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560, 2000
23. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70: 351-357, 2006 (Pubitemid 44086585)
24. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andia JB: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74: 1070-1078, 2008
25. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar- Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168: 397-403, 2008 (Pubitemid 351350586)
26. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004
27. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19: 1613-1619, 2008
28. Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K: Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 17: 38-44, 2007
29. Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, van WD, Greenland S, Kalantar-Zadeh K: Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 3: 1769-1776, 2008
30. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007
31. Repo JM, Rantala IS, Honkanen TT, Mustonen JT, Koobi P, Tahvanainen AM, Niemela OJ, Tikkanen I, Rysa JM, Ruskoaho HJ, Porsti IH: Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 72: 977-984, 2007
32. Arcidiacono MV, Tokumoto M, Marath B, Dusso A: Inhibition of renal TACE expression and activity is a critical determinant of active vitamin D renoprotection in experimental kidney disease [Abstract]. J Am Soc Nephrol 19: 743A, 2008
33. Arcidiacono MV, Tokumoto M, Yang J, Alvarez-Hernandez D, Dusso A: TACE inhibition: A novel strategy for the prevention and treatment of secondary hyperparathyroidism [Abstract]. J Am Soc Nephrol 20: 545A, 2009
34. Greenland S: Introduction to regression modeling. In: Modern epidemiology, 3rd ed., edited by Rothman KS, Greenland S, Lash TL, Philadelphia, Lippincott Williams & Wilkins, 2008, pp 418-455
35. Glymour MM, Greenland S: Causal diagrams. In: Modern epidemiology, 3rd ed., edited by Rothman K, Greenland S, Lash TL, Philadelphia, Lippincott Williams & Wilkins, 2008 pp 183-209
36. Smith GD, Ebrahim S: Mendelian randomization: Prospects, potentials, and limitations. Int J Epidemiol 33: 30-42, 2004
37. Greenland S, Robins J: Invited commentary: Ecologic studies- biases, misconceptions, and counterexamples. Am J Epidemiol 139: 747-760, 1994
38. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
39. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
40. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de ZD, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
41. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006